Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for elderly blood cancer patients: tailored transplant approach shows promise

NCT ID NCT07500753

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Apr 07, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This study tests a new combination of drugs (cladribine, lisaftolax, and busulfan) given before a stem cell transplant in 30 older adults (50+) with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. The goal is to make the transplant safer and more effective, helping patients live longer without the cancer coming back. Participants will be followed to see how long they remain cancer-free and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215006, China

Conditions

Explore the condition pages connected to this study.

MDS (MYELODYSPLASTIC SYNDROME) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)